Jones Financial Companies Lllp Increases Stock Position in Pfizer Inc. $PFE

Key Points

• Jones Financial Companies Lllp increased its stake in Pfizer Inc. by 37.8%, bringing its total holdings to 2,516,211 shares valued at approximately $63.44 million.
• Pfizer reported earnings of $0.78 per share in its last quarterly earnings, surpassing analysts' estimates of $0.58, with quarterly revenue of $14.65 billion.
• The company has announced a quarterly dividend of $0.43, resulting in a 7.2% dividend yield with a payout ratio of 91.49%.

Jones Financial Companies Lllp increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 37.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,516,211 shares of the biopharmaceutical company's stock after purchasing an additional 690,259 shares during the quarter. Jones Financial Companies Lllp's holdings in Pfizer were worth $63,441,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares in the last quarter. Northern Trust Corp increased its stake in shares of Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after purchasing an additional 3,943,397 shares in the last quarter. Amundi increased its stake in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Pfizer by 3.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock worth $1,045,351,000 after purchasing an additional 1,333,740 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Pfizer by 2.8% in the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after buying an additional 838,198 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 3.8%

Shares of PFE traded down $0.95 during midday trading on Friday, reaching $23.91. The stock had a trading volume of 81,158,118 shares, compared to its average volume of 34,996,196. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company's fifty day simple moving average is $24.79 and its two-hundred day simple moving average is $24.28. The company has a market cap of $135.94 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research reports. Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. HSBC cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Finally, Jefferies Financial Group lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.